Brookline Capital Acquisition Corp.

Apexigen, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. The firm’s products include Sotigalimab and APX601. The Sotigalimab is a humanized agonist antibody that targets and activates CD40, a co-stimulatory receptor that is essential for activating both the innate and adaptive arms of the immune system, to stimulate an anti-tumor immune response. The APX601 is a humanized antagonist antibody that binds to TNFR2, which is highly expressed on immune suppressive cells, including Treg and suppressive myeloid cells, as well as on many cancers. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brookline Capital Acquisition Corp. is a blank check company which intends to focus its search on companies in the life sciences industry. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on May 27, 2020 and is headquartered in New York, NY.

New York, NY, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Brookline Capital Acquisition Corp. (NASDAQ: BCACU) (the “Company”) announced today that, commencing February 22, 2021, holders of the 5,750,000 units sold in the Company's initial public offering may elect to separately trade shares of the Company's common stock and warrants included in the units. Common stock and warrants that are separated will trade on The Nasdaq Capital Market under the symbols “BCAC” and “BCACW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Those units not separated will continue to trade on The Nasdaq Capital Markets under the symbol “BCACU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into shares of common stock and warrants.

Brookline Capital Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing February 22, 2021

New York, NY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Brookline Capital Acquisition Corp. (NASDAQ: BCACU) (the “Company”) announced today that it closed its initial public offering of 5,750,000 units, including the exercise in full of the underwriters' 45-day option to purchase up to an additional 750,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds of $57,500,000.

Brookline Capital Acquisition Corp. Completes Closing of $57,500,000 Initial Public Offering

New York, NY, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Brookline Capital Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market (“Nasdaq”) and will begin trading tomorrow, Friday, January 29, 2021, under the ticker symbol “BCACU”. Each unit consists of one share of the Company's common stock and one half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of common stock at a price of $11.50 per share. Only whole warrants are exercisable and will trade.  Once the securities comprising the units begin separate trading, shares of the common stock and warrants are expected to be listed on Nasdaq under the symbols “BCAC” and “BCACW,” respectively.

Brookline Capital Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering

News for Brookline Capital Acquisition Corp. Stock (BCACU)